The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes
Open accessAbstract
OBJECTIVE: Evaluate the effects of two dipeptidyl peptidase-IV (DPP-4) inhibitors, sitagliptin and vildagliptin, known to have different efficacy on mean amplitude of glycemic excursions (MAGE), on oxidative stress, and on systemic inflammatory markers in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: A prospective, randomized, open-label PROBE design (parallel group with a blinded end point) study was performed in 90 patients with type 2 diabetes inadequately controlled by metformin. The study assigned 45 patients to receive sitagliptin (100 mg once daily; sitagliptin group) and 45 patients to receive vildagliptin (50 mg twice daily; vildagliptin group) for 12 weeks. MAGE, evaluated during 48 h of continuous subcutaneous glucose monitoring, allowed an assessment of daily glucose fluctuations at baseline and after 12 weeks in all patients. Assessment of oxidative stress (nitrotyrosine) and systemic levels of inflammatory markers interleukin (IL)-6 and IL-18 was performed at baseline and after 12 weeks in all patients. RESULTS: HbA1c, fasting and postprandial glucose, MAGE, and inflammatory and oxidative stress markers were similar between the groups at baseline. After 12 weeks, MAGE (P < 0.01) was lower in the vildagliptin group than in the sitagliptin group. After treatment, HbA1c and postprandial glucose evidenced similar changes between the groups (P = NS). Vildagliptin treatment was associated with a stronger decrease in nitrotyrosine (P < 0.01), IL-6 (P < 0.05), and IL-18 (P < 0.05) than sitagliptin treatment. Nitrotyrosine and IL-6 changes significantly correlated with changes in MAGE but not in fasting glucose and HbA1c. CONCLUSIONS: MAGE reduction is associated with reduction of oxidative stress and markers of systemic inflammation in type 2 diabetic patients. These effects were greater in the vildagliptin group than in the sitagliptin group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Biochemistry and molecular cell biology of diabetic complications
Brownlee, M. (2001) · Nature · doi:10.1038/414813a · Cited by 9,107
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Monnier, L., Mas, E., Ginet, C., Michel, F., Villon, L., Cristol, J.-P., & Colette, C. (2006) · JAMA · doi:10.1001/jama.295.14.1681 · Cited by 2,444
Ridker, P. M., Rifai, N., Stampfer, M. J., & Hennekens, C. H. (2000) · Circulation · doi:10.1161/01.cir.101.15.1767 · Cited by 2,429
Esposito, K., Nappo, F., Marfella, R., Giugliano, G., Giugliano, F., Ciotola, M., Quagliaro, L., Ceriello, A., & Giugliano, D. (2002) · Circulation · doi:10.1161/01.cir.0000034509.14906.ae · Cited by 1,961 · cited 1×
“Both components lead to diabetes complications through twomajor mechanisms: activation of oxidative stress and increased activity of the innate immune system (7,8).”
BackgroundSelf-citationCoutinho, M., Gerstein, H. C., Wang, Y., & Yusuf, S. (1999) · Diabetes Care · doi:10.2337/diacare.22.2.233 · Cited by 1,685
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461
The Diabetes Control and Complications Trial Research Group (1995) · Diabetes · doi:10.2337/diab.44.8.968 · Cited by 1,301
Mean Amplitude of Glycemic Excursions, a Measure of Diabetic Instability
Service, F. J., Molnar, G. D., Rosevear, J. W., Ackerman, E., Gatewood, L. C., & Taylor, W. F. (1970) · Diabetes · doi:10.2337/diab.19.9.644 · Cited by 1,039
Ischiropoulos, H. (1998) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1998.0755 · Cited by 1,022
Hyperglycemie and Microvascular and Macrovascular Disease in Diabetes
Klein, R. (1995) · Diabetes Care · doi:10.2337/diacare.18.2.258 · Cited by 845
Endothelial dysfunction in diabetes mellitus: Molecular mechanisms and clinical implications
Tabit, C. E., Chung, W. B., Hamburg, N. M., & Vita, J. A. (2010) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-010-9134-4 · Cited by 572
Interleukin-18 Is a Strong Predictor of Cardiovascular Death in Stable and Unstable Angina
Blankenberg, S., Tiret, L., Bickel, C., Peetz, D., Cambien, F., Meyer, J., & Rupprecht, H. J. (2002) · Circulation · doi:10.1161/01.cir.0000020546.30940.92 · Cited by 568
Herman, G. A., Bergman, A., Stevens, C., Kotey, P., Yi, B., Zhao, P., Dietrich, B., Golor, G., Schrodter, A., Keymeulen, B., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1009 · Cited by 495
Shah, Z., Kampfrath, T., Deiuliis, J. A., Zhong, J., Pineda, C., Ying, Z., Xu, X., Lu, B., Moffatt-Bruce, S., Durairaj, R., et al. (2011) · Circulation · doi:10.1161/circulationaha.111.041418 · Cited by 377
Folli, F., Corradi, D., Fanti, P., Davalli, A., Paez, A., Giaccari, A., Perego, C., & Muscogiuri, G. (2011) · Current Diabetes Reviews · doi:10.2174/157339911797415585 · Cited by 376
Covalent Modifiers: An Orthogonal Approach to Drug Design
Potashman, M. H., & Duggan, M. E. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm8008597 · Cited by 346
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.2007.s51 · Cited by 193
IL-6 Deficiency Protects Against Angiotensin II–Induced Endothelial Dysfunction and Hypertrophy
Schrader, L. I., Kinzenbaw, D. A., Johnson, A. W., Faraci, F. M., & Didion, S. P. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.153080 · Cited by 184
Franz, M. J., Bantle, J. M., Beebe, C. A., Brunzell, J. D., Chiasson, J.-L., Garg, A., Ann Holzmeister, L., Hoogwerf, B., Mayer-Davis, E., Mooradian, A., et al. (2002) · Journal of the American Dietetic Association · doi:10.1016/s0002-8223(02)90031-3 · Cited by 166
Epidemiology of risk factors for cardiovascular disease in diabetes and impaired glucose tolerance
Laakso, M., & Lehto, S. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(97)00314-6 · Cited by 161
Measurements of Glucose Control
Service, F. J., O’Brien, P. C., & Rizza, R. A. (1987) · Diabetes Care · doi:10.2337/diacare.10.2.225 · Cited by 140
Wang, J., Alexanian, A., Ying, R., Kizhakekuttu, T. J., Dharmashankar, K., Vasquez-Vivar, J., Gutterman, D. D., & Widlansky, M. E. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.227389 · Cited by 136
Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations
Marfella, R., Barbieri, M., Grella, R., Rizzo, M. R., Nicoletti, G. F., & Paolisso, G. (2009) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2009.01.004 · Cited by 103
Self-citationvan Genugten, R. E., van Raalte, D. H., & Diamant, M. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01473.x · Cited by 77
Folli, F. B., Guzzi, V., Perego, L., Coletta, D. K., Finzi, G., Placidi, C., Rosa, S. L., Capella, C., Socci, C., Lauro, D., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009923 · Cited by 70
Zheng, F., Lu, W., Jia, C., Li, H., Wang, Z., & Jia, W. (2010) · Endocrine · doi:10.1007/s12020-009-9296-6 · Cited by 55
Derosa, G., Maffioli, P., Ferrari, I., Mereu, R., Ragonesi, P. D., Querci, F., Franzetti, I. G., Gadaleta, G., Ciccarelli, L., Piccinni, M. N., et al. (2010) · Hormone and Metabolic Research · doi:10.1055/s-0030-1255036 · Cited by 49
Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with Type 2 diabetes
He, Y., Yamaguchi, M., Ito, H., Terao, S., & Sekiguchi, K. (2010) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp48582 · Cited by 28
Cited by
Diabetes, cardiovascular disease and the microcirculation
Strain, W. D., & Paldánius, P. M. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0703-2 · Cited by 609
Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus
Deacon, C. F. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0399-8 · Cited by 398
Torimoto, K., Okada, Y., Mori, H., & Tanaka, Y. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-1 · Cited by 284
A Very Low-Carbohydrate, Low–Saturated Fat Diet for Type 2 Diabetes Management: A Randomized Trial
Tay, J., Luscombe-Marsh, N. D., Thompson, C. H., Noakes, M., Buckley, J. D., Wittert, G. A., Yancy, W. S., & Brinkworth, G. D. (2014) · Diabetes Care · doi:10.2337/dc14-0845 · Cited by 260
Cardiovascular effects of gliptins
Scheen, A. J. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.183 · Cited by 175
Metadata
- Authors
- Rizzo, M. R., Barbieri, M., Marfella, R., & Paolisso, G.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-09-11
- Volume
- 35
- Issue
- 10
- Pages
- 2076-2082
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2150859826
- Cited by
- 303
- References
- 35
- FWCI
- 23.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.